Carregant...
Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy
Introduction of immune checkpoint inhibitors (ICIs) has led to significant improvements in the treatment of multiple malignancies. Anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) are two essential ICIs that have been FDA approved since 2011. As the use...
Guardat en:
| Publicat a: | Case Rep Oncol Med |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Hindawi
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5698791/ https://ncbi.nlm.nih.gov/pubmed/29250451 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/5063405 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|